PET indications

Current Medicare indications for all diagnostic imaging including PET scans can always be found at www.mbsonline.gov.au

PET scans fall under item numbers 61523 – 61647.

  • 61523 – Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
  • 61524 – Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy
  • 61525 – Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy
  • 61527 – Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to the unavailability of gallium-67
  • 61529 – Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned
  • 61538 – FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy
  • 61541 – Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy
  • 61553 – Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy
  • 61559 – FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery
  • 61560 – FDG PET study of the brain, performed for the diagnosis of Alzheimer’s disease, if:

a) clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and
b) the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and
c) a service to which this item applies has not been performed on the patient in the previous 12 months; and
d) a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer’s disease

  • 61563 – Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent (Applicable once per lifetime)
  • 61564 – Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who:

(a) has undergone prior locoregional therapy; and

(b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation (Applicable twice per lifetime)

  • 61565 – Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy
  • 61571 – Whole body FDG PET study, for the further primary staging of  patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent
  • 61575 – Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent
  • 61577 – Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy
  • 61598 – Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer
  • 61604 – Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy
  • 61610 – Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes
  • 61620 – Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma
  • 61622 – Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma
  • 61628 – Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma
  • 61632 – Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma
  • 61640 – Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable
  • 61646 – Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent
  • 61647 – Whole body 68Ga DOTA peptide PET study, if:

(a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or
(b) both:

(i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and
(ii) the study is for excluding additional disease sites

New indication – from 1 November 2022

  • 61612 – Whole body FDG PET study for the initial staging of eligible cancer types, for a patient who is considered suitable for active therapy, if:
  1. the eligible cancer type is:
    1. a rare or uncommon cancer (less than 12 cases per 100,000 persons per year); and
    2. a typically FDG-avid cancer; and
  2. there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient (Applicable once per cancer diagnosis)

On current Australian cancer data (https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-summary-data-visualisation) this would include the following cancers with no current Medicare item number for PET scans *

Neuroendocrine; Adrenocortical carcinoma, Merkel cell carcinoma, Paraganglioma. Pheochromocytoma
Upper Gastrointestinal; Ampullary cancer, Extrahepatic bile duct cancer, Gallbladder cancer, GIST, Liver cancer, Pancreatic Cancer, Small intestine cancer, Stomach cancer
Lower Gastrointestinal; Anal cancer, Peritoneal cancer
Genitourinary; Bladder cancer, Penile cancer, Peritoneal cancer, Renal pelvis cancer (kidney cancer excl.), Testicular cancer, Ureteral cancer, Urethral cancer
Gynae-Oncology; Cervical (no restriction), Endometrial, Ovarian, Serous carcinomas of the fallopian tube, Peritoneal cancer, Placenta cancer, Urethral cancer, Uterine cancer, Vaginal cancer, Vulval cancer
Haematology; Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Multiple myeloma,
Lung/Thoracic; Mesothelioma, Thymoma, Thymic Carcinomas
Skin; Merkel cell carcinoma
Neuro-Oncology; Brain and other central nervous system cancer
Cancer of Unknown Primary